Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT02325843
Previous Study | Return to List | Next Study

the Treatment of Human Bone Marrow Mesenchymal Stem Cells in Ocular Corneal Burn

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02325843
Recruitment Status : Completed
First Posted : December 25, 2014
Last Update Posted : April 11, 2019
Sponsor:
Information provided by (Responsible Party):
Dan Liang, Sun Yat-sen University

Brief Summary:
Ocular chemical burn is one of the cause of vision loss in our country, and there are no satisfactory treatment. Human bone marrow mesenchymal stem cells (MSC) have the biological characteristics of self-renewal, immune regulation, multidirectional differentiation and tissue repair. Our preliminary research showed that in corneal alkali injury rats, the MSC can accelerated the cornea repair, inhibited angiogenesis. The aim of this study is to access the efficacy and safety of mesenchymal stem cell in the treatment of corneal burn in human.

Condition or disease Intervention/treatment Phase
Chemical Burns Other: human bone marrow MSC Phase 2

Detailed Description:
Corneal burn is a ocular damage disease included chemically burned and thermally burned. Surgery of corneal transplantation,amniotic membrane transplantation are some of effective,however,these therapy are expensive and the transplantation resources are limited. To arrest the inflammatory phase, several types of immunosuppressive treatments have been investigated. Corticosteroids also is important, however, long time usage of corticosteroids often cause severe side-effects. Human bone marrow mesenchymal stem cells (MSC) have the biological characteristics of self -renewal, immune regulation, multidirectional differentiation and tissue repair. Our preliminary research showed that in corneal alkali injury rats, the MSC can accelerated the cornea repair, inhibited angiogenesis. Many animal research also revealed that MSC have effect on the ocular alkali burned. And subconjunctivity injection is efficient, the clinical study of MSC on treating other disease have been developed rapidly recently, in further ,the outcome are encouraging, and no side-effect related MSC was reported, MSC can come from bone marrow, Umbilical cord blood,Adipose tissue and so on, but bone marrow MSC is mostly common used. The investigators propose to assess the efficacy and safety of human bone marrow mesenchymal stem cell in the treatment of corneal burn in human.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 16 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Subconjunctival Injection of Human Bone Marrow Mesenchymal Stem Cells for Ocular Corneal Burn: Prospective, Case Series Study
Study Start Date : July 2015
Actual Primary Completion Date : December 2017
Actual Study Completion Date : December 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Burns

Arm Intervention/treatment
Experimental: human bone marrow MSC
5×106/0.5ml MSC was injected subconjunctival at the inferior fornix.If persistent epithelial defect was noted thereafter, a second AMT and MSC injection was performed.
Other: human bone marrow MSC
The arms of active comparator :human bone marrow MSC subconjunctival injection once time. If persistent epithelial defect was noted thereafter, a second MSC injection was performed.




Primary Outcome Measures :
  1. Incidence of adverse events by subconjunctival injection of BMMSCs [ Time Frame: 6 months ]
    Record the adverse events, including topical complications such as ocular infection, conjunctival necrosis at the injection site, retinal artery occlusion, and systemic complications such as fever, urticaria, hemolysis, hypotension, renal and liver dysfunction, tumor formation, and/or abnormalities in complete blood counts.


Secondary Outcome Measures :
  1. Incidence of corneal perforation rate after subconjunctival injection of BMMSCs [ Time Frame: 6 months ]
    the number of corneal perforation eyes/total eyes

  2. Time of corneal epithelialization [ Time Frame: 6 month ]
    record the time when cornea finish epithelialization

  3. Visual acuity [ Time Frame: 6 month ]
    Use the visual chart to record the decimal visual acuity



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. must be ocular burns including chemically burned or the thermally burned
  2. the severity degree should above the Ⅳ degree,including the Ⅳ degree(according the classification of Dua standard,2001)
  3. the subjects are willing to accept this research,and promise to coordinate with the researchers during the follow up period
  4. the subjects should abide by the laws and rules of the study.
  5. the incident time should be within 2 weeks -

Exclusion Criteria:

  1. the visual acuity is blind in any of the eye
  2. have corneal perforation or have the corneal perforation tendency
  3. have been accepted surgury on eyeball after trauma
  4. IOP≥25mmHg even after antiglaucoma
  5. have the history of other corneal diseaze or surgury
  6. have the history of radiotherapy or surgury in the eyeball
  7. associated with corneal ulcer or endoophthalmitis
  8. uncontrolled hypertension(≥150/95mmHg)
  9. abnormal liver and renal function
  10. the pregancy women -

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02325843


Sponsors and Collaborators
Sun Yat-sen University
Investigators
Layout table for investigator information
Study Chair: Liang Dan, MD Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China
Additional Information:
Publications of Results:
Other Publications:
Layout table for additonal information
Responsible Party: Dan Liang, M.D, Sun Yat-sen University
ClinicalTrials.gov Identifier: NCT02325843    
Other Study ID Numbers: 2014MEKY059
First Posted: December 25, 2014    Key Record Dates
Last Update Posted: April 11, 2019
Last Verified: April 2019
Additional relevant MeSH terms:
Layout table for MeSH terms
Burns
Burns, Chemical
Wounds and Injuries